Intravesical AD 32 (Valrubicin) in Patients With Carcinoma in Situ (CIS) of the Bladder Who Have Failed or Have Recurrence Following Treatment With Bacillus Calmette-guerin (BCG)
Clinical trial NCT01316874 · COMPLETED
Trial details
- NCT number
- NCT01316874
- Sponsor
- Endo USA Inc., a Keenova Therapeutics Company
- Status
- COMPLETED
- Phase
- Phase 2, Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 1993-11-01
- Primary completion
- 1997-04-01
- Enrollment
- 90
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.